Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group

Crizotinib is a multikinase inhibitor, effective in non-small cell lung cancer (NSCLC) harboring mesenchymal-epidermal transition (MET) alterations. Although small prospective studies showed efficacy and safety of crizotinib in NSCLC with MET alterations, there is limited real-life data. Aim of this...

Descripción completa

Detalles Bibliográficos
Autores principales: Gürbüz, Mustafa, Kiliçkap, Saadettin, Bilici, Ahmet, Karadurmuş, Nuri, Sezer, Ahmet, Şendur, Mehmet Ali Nahit, Paydaş, Semra, Artaç, Mehmet, Fulden Yumuk, Perran, Gürsoy, Pinar, Uysal, Mükremin, Şenol Coşkun, Hasan, Tatli, Ali Murat, Selçukbiricik, Fatih, Dişel, Umut, Köksoy, Elif Berna, Güven, Deniz Can, Uğrakli, Muzaffer, Akkuş, Erman, Yücel, Şebnem, Erol, Cihan, Karakaya, Serdar, Şakalar, Teoman, Khanmammadov, Nijat, Paksoy, Nail, Demirkazik, Ahmet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771320/
https://www.ncbi.nlm.nih.gov/pubmed/36550824
http://dx.doi.org/10.1097/MD.0000000000032368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771320/
https://www.ncbi.nlm.nih.gov/pubmed/36550824
http://dx.doi.org/10.1097/MD.0000000000032368

Ejemplares similares